Explore GPCR-targeting therapies and their untapped potential in drug development, making up 30-35 percent of approved drugs.

Historically, GPCRs have been one of the most important targets for drug discovery. In fact, around 30 % of all currently marketed drugs target GPCRs. Despite this, a significant number of GPCRs ...

Because they are involved in so many sensory and physiological processes, including diseases such as cancer, they are the targets of a large number of currently available drugs. In this article, ...

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic ...

Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Wegovy maker Novo Nordisk has hired the start-up Deep Apple Therapeutics to develop small molecules as its next weight-loss ...

Salipro Biotech & Daewoong Pharmaceutical collaborate to advance development of novel therapeutics: Seoul, Korea Thursday, June 12, 2025, 16:00 Hrs [IST] Swedish biotech company S ...

Partnership combines AbTherx's proprietary Atlas Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / AC ...

The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging ...